title: Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans.
abstract: To understand the in vivo metabolism of dietary gamma-linolenic acid (GLA), we supplemented the diets of 29 volunteers with GLA in doses of 1.5-6.0 g/d. Twenty-four subjects ate controlled eucaloric diets consisting of 25% fat; the remaining subjects maintained their typical Western diets. GLA and dihomo-gamma-linolenic acid (DGLA) increased in serum lipids of subjects supplemented with 3.0 and 6.0 g/d; serum arachidonic acid increased in all subjects. GLA supplementation with 3.0 and 6.0 g/d also resulted in an enrichment of DGLA in neutrophil phospholipids but no change in GLA or AA levels. Before supplementation, DGLA was associated primarily with phosphatidylethanolamine (PE) of neutrophil glycerolipids, and DGLA increased significantly in PE and neutral lipids after GLA supplementation. Extending the supplementation to 12 wk did not consistently change the magnitude of increase in either serum or neutrophil lipids in subjects receiving 3.0 g/d. After GLA supplementation, A23187-stimulated neutrophils released significantly more DGLA, but AA release did not change. Neutrophils obtained from subjects after 3 wk of supplementation with 3.0 g/d GLA synthesized less leukotriene B4 (P < 0.05) and platelet-activating factor. Together, these data reveal that DGLA, the elongase product of GLA, but not AA accumulates in neutrophil glycerolipids after GLA supplementation. The increase in DGLA relative to AA within inflammatory cells such as the neutrophil may attenuate the biosynthesis of AA metabolites and may represent a mechanism by which dietary GLA exerts an anti-inflammatory effect.
authors.affiliation: Department of Internal Medicine, Section on Pulmonary and Critical Care Medicine, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27157-1054, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Johnson
authors.forename: D D
authors.initials: DD
authors.lastname: Swan
authors.forename: M E
authors.initials: ME
authors.lastname: Surette
authors.forename: J
authors.initials: J
authors.lastname: Stegner
authors.forename: T
authors.initials: T
authors.lastname: Chilton
authors.forename: A N
authors.initials: AN
authors.lastname: Fonteh
authors.forename: F H
authors.initials: FH
authors.lastname: Chilton
mesh_terms: D015126:8,11,14-Eicosatrienoic Acid / Q000008:administration & dosage / Q000378:metabolism; D000328:Adult; D015777:Eicosanoids / Q000096:biosynthesis*; D005260:Female; D005527:Food, Fortified; D006801:Humans; D007975:Leukotriene B4 / Q000096:biosynthesis; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D017965:gamma-Linolenic Acid / Q000008:administration & dosage / Q000378:metabolism*
chemical_list: D015777:Eicosanoids; D008055:Lipids; D007975:Leukotriene B4; D017965:gamma-Linolenic Acid; D015126:8,11,14-Eicosatrienoic Acid